20.500.12556/DiRROS-28622 Four years on pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024) Background: Family planning is an important aspect of multiple sclerosis (MS), and neuromyelitis optica spectrum disorder (NMOSD) management. Knowledge gaps remain, including optimal perinatal management strategies, and fetal risks associated with disease-modifying therapy (DMT) exposure. Objective: To describe perinatal DMT use, together with pregnancy and neonatal outcomes prospectively recorded in the International MSBase Pregnancy and Women's Health Registry. Methods: We report summary statistics for data collected between May 2020 and August 2024. Results: A total of 1887 relapsing-remitting MS (RRMS), 12 primary-progressive MS (PPMS), 2 radiologically isolated syndrome (RIS) and 21 NMOSD completed pregnancies were recorded, including 1644 (85.5%) live births, 208 (10.8%) miscarriages, and 6 (0.3%) neonatal deaths. Most women had unassisted (53.8%) or assisted (7.4%) vaginal births. Seventy five percent of pregnancies had DMT exposures within 6 months preconception; 19% of NMOSD, and 62% of MS pregnancies were DMT-exposed during gestation; 18.1% of pregnancies reported in-pregnancy monoclonal antibody DMT exposure. No overt safety signals were seen. Conclusion: This first report from the newly launched MSBase pregnancy registry, establishes an increasing number of pregnancies being conceived on monoclonal antibody therapies. Although no safety signals were observed, it is important to continue monitoring for safety signals in real-world databases as the use of highly effective therapies continues to increase perinatally. multiple slerosis disease-modifying therapy neonatal outcomes neuromyelitis optica spectrum disorder pregnancy multipla skleroza terapija ki spreminja potek bolezni neonatalni izidi motnja optičnega spektra nevromielitisa nosečnost true false true Angleški jezik Slovenski jezik Neznano 2026-03-26 09:19:49 2026-03-26 09:19:49 2026-03-28 03:43:11 0000-00-00 00:00:00 2025 0 0 str. 1088-1101 iss. 9 Vol. 31 Aug. 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.8:618.2/.7 1352-4585 10.1177/13524585251349125 270993411 RAZ_Jokubaitis_Vilija_G._2025.pdf RAZ_Jokubaitis_Vilija_G._2025.pdf 1 7427586C21292CE48189C6BA2B1F14A8 cee28cefdab4e173bf498176d7619855d91e88faeac5e89f08996a9a047cb280 c6452c63-28ec-11f1-aa40-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=42518 https://journals.sagepub.com/doi/epdf/10.1177/13524585251349125 1 90efc344-28ec-11f1-aa40-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=42516 Univerzitetni klinični center Ljubljana 0 0 0